Aptevo Therapeutics Inc (APVO)

May 01, 2026

APVO Forecast, Price Target & Analyst Ratings | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill

May 01, 2026

Apr 27, 2026

Aptevo Therapeutics shares jump after $60 million equity facility secured - MSN

Apr 27, 2026

Apr 25, 2026

Aptevo Therapeutics (APVO) upgraded to buy: Here's why - MSN

Apr 25, 2026

Apr 24, 2026

APVO Price History for Aptevo Therapeutics Stock - Barchart.com

Apr 24, 2026

Apr 22, 2026

APVO Aptevo Therapeutics Inc. reports vastly stronger Q4 2025 EPS than expected, shares climb 7.16 percent today.Social Trade Signals - UBND thành phố Hải Phòng

Apr 22, 2026

Apr 22, 2026

Aptevo Therapeutics posts 99.9% EPS surprise far narrower loss than expectedCommunity Momentum Stocks - Xã Thanh Hà

Apr 22, 2026

Apr 22, 2026

Aptevo (APVO) Stock Technical Trade (Investors Pile In) 2026-04-22Shared Momentum Picks - Cổng thông tin điện tử Tỉnh Sơn La

Apr 22, 2026

Apr 20, 2026

Aptevo (APVO) Stock: Fast Summary (Weakens) 2026-04-20Fast Moving Stocks - UBND thành phố Hải Phòng

Apr 20, 2026

Apr 13, 2026

Risk On: Is Aptevo Therapeutics Inc impacted by rising ratesPortfolio Update Report & AI Driven Price Forecasts - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Aug Chart Watch: What is Aptevo Therapeutics Incs valuation compared to sector2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Can Aptevo (APVO) Stock Beat the Market | Price at $4.45, Up 1.60%Momentum Investing - Cổng thông tin điện tử Tỉnh Sơn La

Apr 13, 2026

Apr 11, 2026

Aug Swings: Is The Honest Company Inc stock risky to hold nowMarket Movement Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Aptevo Therapeutics (APVO) Raised to Buy: Discover the Reasons - Bitget

Apr 10, 2026

Apr 10, 2026

Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why - Yahoo Finance

Apr 10, 2026

Apr 10, 2026

Is Aptevo (APVO) Stock Showing Strength | Price at $4.45, Up 1.83%Buy Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 10, 2026

Apr 09, 2026

Tech Rally: Is Aptevo Therapeutics Inc impacted by rising rates2026 Sector Review & Real-Time Chart Breakout Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 07, 2026

APVO Should I Buy - Intellectia AI

Apr 07, 2026

Apr 06, 2026

Is Aptevo (APVO) Stock Attractive Now | Price at $4.23, Up 3.17%Open Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La

Apr 06, 2026

Apr 04, 2026

APVO Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Mar 31, 2026

Update Recap: Can Aptevo Therapeutics Inc sustain its profitabilityMarket Movers & Risk Managed Investment Signals - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Institution Moves: Will IBEX outperform during market ralliesWeekly Risk Summary & Smart Allocation Stock Tips - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Nasdaq Moves: What are Aptevo Therapeutics Incs recent SEC filings showing2026 Buyback Activity & Expert Curated Trade Setups - baoquankhu1.vn

Mar 31, 2026

Mar 29, 2026

Risk Report: Is Aptevo Therapeutics Inc impacted by rising rates2026 Price Targets & AI Enhanced Trade Execution Alerts - baoquankhu1.vn

Mar 29, 2026

Mar 27, 2026

Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo

Mar 27, 2026

Mar 27, 2026

Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate in Frontline AML Trial - citybuzz -

Mar 27, 2026

Mar 27, 2026

Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment - NewMediaWire

Mar 27, 2026

Mar 27, 2026

Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | Corporate - EQS News

Mar 27, 2026

Mar 27, 2026

Aptevo Rises on AML Data—But Will It Hold? - Bitget

Mar 27, 2026

Mar 26, 2026

Aptevo Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Mar 26, 2026

Mar 26, 2026

10-K - sec.gov

Mar 26, 2026

Mar 26, 2026

Aptevo Therapeutics 10-K: Net loss $25.97M, EPS $(87.27) - TradingView

Mar 26, 2026

Mar 26, 2026

Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data - Stock Titan

Mar 26, 2026

Mar 26, 2026

[8-K] Aptevo Therapeutics Inc. Reports Material Event - Stock Titan

Mar 26, 2026

Mar 26, 2026

APVO Achieves Significant Advances in Clinical Pipeline and Capi - GuruFocus

Mar 26, 2026

Mar 26, 2026

Aptevo Provides State of the Business Report and 2025 Financial Results - Bitget

Mar 26, 2026

Mar 26, 2026

Aptevo (APVO) Strengthens Financial Position for Future Operatio - GuruFocus

Mar 26, 2026

Mar 26, 2026

No CRS in 28 AML patients as Aptevo adds 3 CD3 drug candidates - Stock Titan

Mar 26, 2026

Mar 26, 2026

APVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 26, 2026

Mar 25, 2026

Aptevo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 25, 2026

Mar 20, 2026

Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | AP81 | US03835L5049 - marketscreener.com

Mar 20, 2026

Mar 19, 2026

Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | APVO | US03835L4059 - marketscreener.com

Mar 19, 2026

Mar 19, 2026

Aptevo to Participate in March 2026 Conferences - ACCESS Newswire

Mar 19, 2026

Mar 19, 2026

Aptevo sends incoming CEO to Roth, spotlights trispecific drugs in Lisbon - Stock Titan

Mar 19, 2026